View in EDS HTML Full Text PDF Full Text

Neutralizing antibody responses to the primary series of a COVID-19 mRNA vaccine in the cancer cohort under active treatment.

Saved in:
Bibliographic Details
Title: Neutralizing antibody responses to the primary series of a COVID-19 mRNA vaccine in the cancer cohort under active treatment.
Authors: Xue H; Vaccine, Immunity and Cancer Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, USA., Kemp TJ; Vaccine, Immunity and Cancer Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, USA., Li C; Vaccine, Immunity and Cancer Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, USA., Roche NV; Vaccine, Immunity and Cancer Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, USA., Bakouny Z; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Labaki C; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA., Lee GM; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA., Trowbridge R; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA., Strauss S; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA., Hughes ME; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA., Lin NU; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA., Choueiri TK; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA., Pinto LA; Vaccine, Immunity and Cancer Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
Source: Human vaccines & immunotherapeutics [Hum Vaccin Immunother] 2025 Dec; Vol. 21 (1), pp. 2589647. Date of Electronic Publication: 2025 Nov 27.
Publication Type: Journal Article
Journal Info: Publisher: Taylor & Francis Country of Publication: United States NLM ID: 101572652 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2164-554X (Electronic) Linking ISSN: 21645515 NLM ISO Abbreviation: Hum Vaccin Immunother Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 41311198
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Neutralizing antibody responses to the primary series of a COVID-19 mRNA vaccine in the cancer cohort under active treatment.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Xue+H%22">Xue H</searchLink>; Vaccine, Immunity and Cancer Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.<br /><searchLink fieldCode="AU" term="%22Kemp+TJ%22">Kemp TJ</searchLink>; Vaccine, Immunity and Cancer Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.<br /><searchLink fieldCode="AU" term="%22Li+C%22">Li C</searchLink>; Vaccine, Immunity and Cancer Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.<br /><searchLink fieldCode="AU" term="%22Roche+NV%22">Roche NV</searchLink>; Vaccine, Immunity and Cancer Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.<br /><searchLink fieldCode="AU" term="%22Bakouny+Z%22">Bakouny Z</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.<br /><searchLink fieldCode="AU" term="%22Labaki+C%22">Labaki C</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Lee+GM%22">Lee GM</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Trowbridge+R%22">Trowbridge R</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Strauss+S%22">Strauss S</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Hughes+ME%22">Hughes ME</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Lin+NU%22">Lin NU</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Choueiri+TK%22">Choueiri TK</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Pinto+LA%22">Pinto LA</searchLink>; Vaccine, Immunity and Cancer Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101572652%22">Human vaccines & immunotherapeutics</searchLink> [Hum Vaccin Immunother] 2025 Dec; Vol. 21 (1), pp. 2589647. <i>Date of Electronic Publication: </i>2025 Nov 27.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Taylor+%26+Francis%22">Taylor & Francis </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101572652 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2164-554X (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2221645515%22">21645515 </searchLink><i>NLM ISO Abbreviation: </i>Hum Vaccin Immunother <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41311198
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1080/21645515.2025.2589647
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 2589647
    Titles:
      – TitleFull: Neutralizing antibody responses to the primary series of a COVID-19 mRNA vaccine in the cancer cohort under active treatment.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Xue H
      – PersonEntity:
          Name:
            NameFull: Kemp TJ
      – PersonEntity:
          Name:
            NameFull: Li C
      – PersonEntity:
          Name:
            NameFull: Roche NV
      – PersonEntity:
          Name:
            NameFull: Bakouny Z
      – PersonEntity:
          Name:
            NameFull: Labaki C
      – PersonEntity:
          Name:
            NameFull: Lee GM
      – PersonEntity:
          Name:
            NameFull: Trowbridge R
      – PersonEntity:
          Name:
            NameFull: Strauss S
      – PersonEntity:
          Name:
            NameFull: Hughes ME
      – PersonEntity:
          Name:
            NameFull: Lin NU
      – PersonEntity:
          Name:
            NameFull: Choueiri TK
      – PersonEntity:
          Name:
            NameFull: Pinto LA
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 12
              Text: 2025 Dec
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 2164-554X
          Numbering:
            – Type: volume
              Value: 21
            – Type: issue
              Value: 1
          Titles:
            – TitleFull: Human vaccines & immunotherapeutics
              Type: main
ResultId 1